Qyuns Therapeutics Co Ltd Ordinary Shares - Class H 02509
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$24.05
- Day Range
- HK$22.75–27.55
- 52-Week Range
- HK$14.00–30.95
- Bid/Ask
- HK$23.20 / HK$26.10
- Market Cap
- HK$5.15 Bil
- Volume/Avg
- 42,000 / 70,619
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 108.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 325
- Website
- http://www.qyuns.net
Comparables
Valuation
|
Metric
|
02509
|
SVA
|
430047
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 23.52 | — |
Price/Book Value | 35.24 | 1.82 | 9.30 |
Price/Sales | 108.12 | 1.83 | 44.84 |
Price/Cash Flow | — | 8.10 | — |
Price/Earnings
02509
SVA
430047
Financial Strength
|
Metric
|
02509
|
SVA
|
430047
|
|---|---|---|---|
Quick Ratio | 1.70 | 11.22 | 3.53 |
Current Ratio | 1.86 | 11.39 | 3.87 |
Interest Coverage | −18.42 | −59.95 | −127.19 |
Quick Ratio
02509
SVA
430047
Profitability
|
Metric
|
02509
|
SVA
|
430047
|
|---|---|---|---|
Return on Assets (Normalized) | −47.40% | −0.81% | −9.36% |
Return on Equity (Normalized) | −341.08% | −1.25% | −15.90% |
Return on Invested Capital (Normalized) | −56.34% | −1.48% | −13.55% |
Return on Assets
02509
SVA
430047
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tsjylhpth | Twy | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vmrdpkpr | Qwprz | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Csmflyqf | Glxtgx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xvqrwjjgt | Prhdswj | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gvywcdbm | Hhjk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vqtkvxdw | Wbmnq | $28.1 Bil | |||
| Moderna Inc
MRNA
| Rjpxqsnd | Xxyyh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hvwpxtyg | Gzlg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hmgybdzpp | Mjrsp | $13.4 Bil | |||
| Incyte Corp
INCY
| Frlvstvb | Whhwkl | $12.7 Bil |
United States